Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10407291 | PMC |
http://dx.doi.org/10.1016/j.jdin.2023.04.016 | DOI Listing |
J Cutan Pathol
January 2025
Division of Dermatology, The University of Texas at Austin, Dell Medical School, Austin, Texas, USA.
Pemetrexed is a chemotherapeutic, antimetabolite agent that has been used in oncology to treat diseases such as metastatic non-small cell lung cancer and unresectable malignant pleural mesothelioma. Pemetrexed use may result in pseudocellulitis, which presents as poorly demarcated patches or plaques with erythema, edema, warmth, and tenderness. These lesions can present unilaterally or bilaterally on the lower extremities.
View Article and Find Full Text PDFJ Fr Ophtalmol
September 2024
Department of Pathology, Ankara University Faculty of Medicine, Ankara, Turkey.
JAAD Case Rep
August 2023
Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.
JAAD Int
September 2023
Department of Dermatology, Yale School of Medicine, New Haven, Connecticut.
Int Ophthalmol
January 2022
Ophthalmic Pathology Laboratory (SJ, DKM), L V Prasad Eye Institute, Hyderabad, India.
Purpose: To study the correlation between retinoblastoma (RB) associated with orbital pseudocellulitis and high-risk histopathology features.
Methods: Retrospective study of 32 patients who underwent primary enucleation for RB presenting with orbital pseudocellulitis.
Results: All RB patients presented with orbital pseudocellulitis.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!